期刊
TRENDS IN MOLECULAR MEDICINE
卷 13, 期 4, 页码 150-157出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2007.02.003
关键词
-
资金
- NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER
- NCI NIH HHS [P30 CA006973] Funding Source: Medline
Over 95% of patients with small-cell lung cancer [SCLC) die within five years of diagnosis. The standard of care and the dismal prognosis for this disease have not changed significantly over the past 25 years. Some of the characteristics of SCLC that have defined it as a particularly virulent form of cancer - rapid proliferation, excessive metabolic and angiogenic dependence, apoptotic imbalance and genetic instability - are now being pursued as tumor-specific targets for intervention both in preclinical and early phase clinical studies. Here, we summarize areas of ongoing anti-cancer drug development, including classes of agents that target essential pathways regulating proliferation, angiogenesis, apoptotic resistance, chromosomal and protein stability, and cell-cell and cell-matrix interaction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据